Overview of epidemiology and contribution of obesity to cardiovascular disease

Progress in Cardiovascular Diseases

Volumn 56, Issue 4, 2014, Pages 369-381

  Bastien, Marjorie ^a,b   Poirier, Paul ^a,b   Lemieux, Isabelle ^a,b   Després, Jean Pierre ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Cardiovascular disease; CV risks; Ectopic fat; Obesity

Indexed keywords

ADIPOCYTOKINE; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADIPOSE TISSUE; ANTHROPOMETRY; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL; BODY MASS; BODY WEIGHT; BRAIN; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; FAT BODY; FAT INTAKE; FEMALE; HEART; HUMAN; INSULIN RESISTANCE; LEAN BODY WEIGHT; LIPOPROTEIN BLOOD LEVEL; LIVER; MALE; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OBESITY; PREVALENCE; SKELETAL MUSCLE; SURVIVAL; TRIACYLGLYCEROL BLOOD LEVEL;

BF; BMI; BODY FAT; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR; CARDIOVASCULAR DISEASE; CHD; CORONARY HEART DISEASE; CRP; CV; CV RISKS; CVD; DIABETES MELLITUS; DM; ECTOPIC FAT; FFAS; FREE FATTY ACIDS; HDL; HEART FAILURE; HF; HIGH-DENSITY LIPOPROTEIN; HTN; HYPERTENSION; IL; INTERLEUKIN; LDL; LEFT VENTRICULAR; LEFT VENTRICULAR HYPERTROPHY; LEFT VENTRICULAR MASS; LOW-DENSITY LIPOPROTEIN; LV; LVH; LVM; MI; MYOCARDIAL INFARCTION; NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY; NHANES; NON-ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NSTEMI; OBESITY; TGS; TNF; TRIGLYCERIDES; TUMOR NECROSIS FACTOR; VERY LOW-DENSITY LIPOPROTEIN; VLDL; WAIST CIRCUMFERENCE; WAIST-TO-HIP RATIO; WC; WHR;

ABDOMINAL FAT; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; BODY FAT DISTRIBUTION; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHILD; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; OBESITY, MORBID; PEDIATRIC OBESITY; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; SEX DISTRIBUTION; WORLD HEALTH;

EID: 84892408871     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2013.10.016     Document Type: Article

References (128)

1. Global Health Observatory (GHO): Obesity 2008. World Health Organisation 2013 http://www.who.int/gho/ncd/risk_factors/obesity_text/en/index.html.
2. Flegal K.M., Carroll M.D., Ogden C.L., Curtin L.R. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303(3):235-241.
3. Flegal K.M., Carroll M.D., Kuczmarski R.J., Johnson C.L. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998, 22(1):39-47.
4. Flegal K.M., Carroll M.D., Ogden C.L., Johnson C.L. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002, 288(14):1723-1727.
5. Flegal K.M., Carroll M.D., Kit B.K., Ogden C.L. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012, 307(5):491-497.
6. Composition corporelle des adultes canadiens, 2009 à 2011. Stat Can 2013, ISSN 1920-8774.
7. Olshansky S.J., Passaro D.J., Hershow R.C., et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005, 352(11):1138-1145.
8. Wilkins K., Campbell N.R., Joffres M.R., et al. Blood pressure in Canadian adults. Health Rep 2010, 21(1):37-46.
9. Poirier P., Giles T.D., Bray G.A., et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006, 113(6):898-918.
10. Wormser D., Kaptoge S., Di A.E., et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 2011, 377(9771):1085-1095.
11. Poirier P., Giles T.D., Bray G.A., et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 2006, 26(5):968-976.
12. Poirier P., Eckel R.H. Obesity and cardiovascular disease. Curr Atheroscler Rep 2002, 4(6):448-453.
13. Rabkin S.W., Mathewson F.A., Hsu P.H. Relation of body weight to development of ischemic heart disease in a cohort of young North American men after a 26year observation period: the Manitoba Study. Am J Cardiol 1977, 39(3):452-458.
14. Hubert H.B., Feinleib M., McNamara P.M., Castelli W.P. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983, 67(5):968-977.
15. Rossi R., Iaccarino D., Nuzzo A., et al. Influence of body mass index on extent of coronary atherosclerosis and cardiac events in a cohort of patients at risk of coronary artery disease. Nutr Metab Cardiovasc Dis 2011, 21(2):86-93.
16. Engeland A., Bjorge T., Sogaard A.J., Tverdal A. Body mass index in adolescence in relation to total mortality: 32-year follow-up of 227,000 Norwegian boys and girls. Am J Epidemiol 2003, 157(6):517-523.
17. Flegal K.M., Kit B.K., Orpana H., Graubard B.I. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013, 309(1):71-82.
18. Franks P.W., Hanson R.L., Knowler W.C., Sievers M.L., Bennett P.H., Looker H.C. Childhood obesity, other cardiovascular risk factors, and premature death. N Engl J Med 2010, 362(6):485-493.
19. Must A., Jacques P.F., Dallal G.E., Bajema C.J., Dietz W.H. Long-term morbidity and mortality of overweight adolescents. A follow-up of the Harvard Growth Study of 1922 to 1935. N Engl J Med 1992, 327(19):1350-1355.
20. Poirier P., Cornier M.A., Mazzone T., et al. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation 2011, 123(15):1683-1701.
21. Poirier P., Alpert M.A., Fleisher L.A., et al. Cardiovascular evaluation and management of severely obese patients undergoing surgery: a science advisory from the American Heart Association. Circulation 2009, 120(1):86-95.
22. Romero-Corral A., Montori V.M., Somers V.K., et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 2006, 368(9536):666-678.
23. Calle E.E., Thun M.J., Petrelli J.M., Rodriguez C., Heath C.W. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999, 341(15):1097-1105.
24. Romero-Corral A., Somers V.K., Sierra-Johnson J., et al. Diagnostic performance of body mass index to detect obesity in patients with coronary artery disease. Eur Heart J 2007, 28(17):2087-2093.
25. Poirier P. Adiposity and cardiovascular disease: are we using the right definition of obesity?. Eur Heart J 2007, 28(17):2047-2048.
26. Hamer M., Stamatakis E. Overweight and obese cardiac patients have better prognosis despite reporting worse perceived health and more conventional risk factors. Prev Med 2013, 57(1):12-16.
27. Dagenais G.R., Yi Q., Mann J.F., Bosch J., Pogue J., Yusuf S. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 2005, 149(1):54-60.
28. Kragelund C., Hassager C., Hildebrandt P., Torp-Pedersen C., Kober L. Impact of obesity on long-term prognosis following acute myocardial infarction. Int J Cardiol 2005, 98(1):123-131.
29. de Koning L., Merchant A.T., Pogue J., Anand S.S. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J 2007, 28(7):850-856.
30. Lavie C.J., De S.A., Patel D.A., Romero-Corral A., Artham S.M., Milani R.V. Body composition and survival in stable coronary heart disease: impact of lean mass index and body fat in the "obesity paradox". J Am Coll Cardiol 2012, 60(15):1374-1380.
31. Despres J.P., Moorjani S., Lupien P.J., Tremblay A., Nadeau A., Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990, 10(4):497-511.
32. Despres J.P. Body fat distribution and risk of cardiovascular disease: an update. Circulation 2012, 126(10):1301-1313.
33. Cornier M.A., Despres J.P., Davis N., et al. Assessing adiposity: a scientific statement from the American Heart Association. Circulation 2011, 124(18):1996-2019.
34. Liu J., Fox C.S., Hickson D., Bidulescu A., Carr J.J., Taylor H.A. Fatty liver, abdominal visceral fat, and cardiometabolic risk factors: the Jackson Heart Study. Arterioscler Thromb Vasc Biol 2011, 31(11):2715-2722.
35. Liu J., Fox C.S., Hickson D.A., et al. Impact of abdominal visceral and subcutaneous adipose tissue on cardiometabolic risk factors: the Jackson Heart Study. J Clin Endocrinol Metab 2010, 95(12):5419-5426.
36. Rosito G.A., Massaro J.M., Hoffmann U., et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation 2008, 117(5):605-613.
37. Kamel E.G., McNeill G., Han T.S., et al. Measurement of abdominal fat by magnetic resonance imaging, dual-energy X-ray absorptiometry and anthropometry in non-obese men and women. Int J Obes Relat Metab Disord 1999, 23(7):686-692.
38. Onat A., Avci G.S., Barlan M.M., Uyarel H., Uzunlar B., Sansoy V. Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. Int J Obes Relat Metab Disord 2004, 28(8):1018-1025.
39. Waist circumference and waist-hip ratio: report of a WHO expert consultation 2008, World Health Organization, Geneva, ISBN 978 92 4 150149.
40. Mathieu P., Poirier P., Pibarot P., Lemieux I., Despres J.P. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension 2009, 53(4):577-584.
41. Poirier P., Martin J., Marceau P., Biron S., Marceau S. Impact of bariatric surgery on cardiac structure, function and clinical manifestations in morbid obesity. Expert Rev Cardiovasc Ther 2004, 2(2):193-201.
42. Kenchaiah S., Evans J.C., Levy D., et al. Obesity and the risk of heart failure. N Engl J Med 2002, 347(5):305-313.
43. Kaltman A.J., Goldring R.M. Role of circulatory congestion in the cardiorespiratory failure of obesity. Am J Med 1976, 60(5):645-653.
44. Messerli F.H., Nunez B.D., Ventura H.O., Snyder D.W. Overweight and sudden death. Increased ventricular ectopy in cardiopathy of obesity. Arch Intern Med 1987, 147(10):1725-1728.
45. Messerli F.H. Cardiopathy of obesity-a not-so-Victorian disease. N Engl J Med 1986, 314(6):378-380.
46. Ku C.S., Lin S.L., Wang D.J., Chang S.K., Lee W.J. Left ventricular filling in young normotensive obese adults. Am J Cardiol 1994, 73(8):613-615.
47. Martin J., Bergeron S., Pibarot P., et al. Impact of Bariatric Surgery on N-Terminal Fragment of the Prohormone Brain Natriuretic Peptide and Left Ventricular Diastolic Function. Can J Cardiol 2013, 29(8):969-975.
48. Brassard P., Legault S., Garneau C., Bogaty P., Dumesnil J.G., Poirier P. Normalization of diastolic dysfunction in type 2 diabetics after exercise training. Med Sci Sports Exerc 2007, 39(11):1896-1901.
49. Lauer M.S., Anderson K.M., Kannel W.B., Levy D. The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study. JAMA 1991, 266(2):231-236.
50. Alpert M.A., Lambert C.R., Panayiotou H., et al. Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. Am J Cardiol 1995, 76(16):1194-1197.
51. Neeland I.J., Gupta S., Ayers C.R., et al. Relation of regional fat distribution to left ventricular structure and function. Circ Cardiovasc Imaging 2013, 6(5):800-807.
52. Turkbey E.B., McClelland R.L., Kronmal R.A., et al. The impact of obesity on the left ventricle: the Multi-Ethnic Study of Atherosclerosis (MESA). JACC Cardiovasc Imaging 2010, 3(3):266-274.
53. de Jonge L.L., van Osch-Gevers L., Willemsen S.P., et al. Growth, obesity, and cardiac structures in early childhood: the Generation R Study. Hypertension 2011, 57(5):934-940.
54. Cote A.T., Harris K.C., Panagiotopoulos C., Sandor G.G., Devlin A.M. Childhood Obesity and Cardiovascular Dysfunction. J Am Coll Cardiol 2013, 62(15):1309-1319.
55. Shimabukuro M., Hirata Y., Tabata M., et al. Epicardial adipose tissue volume and adipocytokine imbalance are strongly linked to human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2013, 33(5):1077-1084.
56. Vela D., Buja L.M., Madjid M., et al. The role of periadventitial fat in atherosclerosis. Arch Pathol Lab Med 2007, 131(3):481-487.
57. Iacobellis G., Sharma A.M. Epicardial adipose tissue as new cardio-metabolic risk marker and potential therapeutic target in the metabolic syndrome. Curr Pharm Des 2007, 13(21):2180-2184.
58. Baker A.R., Silva N.F., Quinn D.W., et al. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol 2006, 5:1.
59. Balsaver A.M., Morales A.R., Whitehouse F.W. Fat infiltration of myocardium as a cause of cardiac conduction defect. Am J Cardiol 1967, 19(2):261-265.
60. Spain D.M., Cathcart R.T. Heart block caused by fat infiltration of the interventricular septum (cor adiposum). Am Heart J 1946, 32(5):659-664.
61. Dervan J.P., Ilercil A., Kane P.B., Anagnostopoulos C. Fatty infiltration: another restrictive cardiomyopathic pattern. Cathet Cardiovasc Diagn 1991, 22(3):184-189.
62. Lusis A.J. Atherosclerosis. Nature 2000, 407(6801):233-241.
63. Wilson P.W., D'Agostino R.B., Sullivan L., Parise H., Kannel W.B. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002, 162(16):1867-1872.
64. Bibbins-Domingo K., Coxson P., Pletcher M.J., Lightwood J., Goldman L. Adolescent overweight and future adult coronary heart disease. N Engl J Med 2007, 357(23):2371-2379.
65. McGill H.C., McMahan C.A., Herderick E.E., Malcom G.T., Tracy R.E., Strong J.P. Origin of atherosclerosis in childhood and adolescence. Am J Clin Nutr 2000, 72(5 Suppl.):1307S-1315S.
66. Berenson G.S. Bogalusa Heart Study: a long-term community study of a rural biracial (black/white) population. Am J Med Sci 2001, 322(5):267-274.
67. Enos W.F., Holmes R.H., Beyer J. Coronary disease among United States soldiers killed in action in Korea; preliminary report. J Am Med Assoc 1953, 152(12):1090-1093.
68. McGill H.C., McMahan C.A., Malcom G.T., Oalmann M.C., Strong J.P. Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol 1995, 15(4):431-440.
69. Freedman D.S., Dietz W.H., Tang R., et al. The relation of obesity throughout life to carotid intima-media thickness in adulthood: the Bogalusa Heart Study. Int J Obes Relat Metab Disord 2004, 28(1):159-166.
70. Kortelainen M.L., Sarkioja T. Visceral fat and coronary pathology in male adolescents. Int J Obes Relat Metab Disord 2001, 25(2):228-232.
71. Arcaro G., Zamboni M., Rossi L., et al. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity. Int J Obes Relat Metab Disord 1999, 23(9):936-942.
72. Sturm W., Sandhofer A., Engl J., et al. Influence of visceral obesity and liver fat on vascular structure and function in obese subjects. Obesity (Silver Spring) 2009, 17(9):1783-1788.
73. Flavahan N.A., Vanhoutte P.M. Endothelial cell signaling and endothelial dysfunction. Am J Hypertens 1995, 8(5 Pt 2):28S-41S.
74. Bucerius J., Duivenvoorden R., Mani V., et al. Prevalence and risk factors of carotid vessel wall inflammation in coronary artery disease patients: FDG-PET and CT imaging study. JACC Cardiovasc Imaging 2011, 4(11):1195-1205.
75. Rocha V.Z., Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 2009, 6(6):399-409.
76. Van Gaal L.F., Mertens I.L., De Block C.E. Mechanisms linking obesity with cardiovascular disease. Nature 2006, 444(7121):875-880.
77. Visser M., Bouter L.M., McQuillan G.M., Wener M.H., Harris T.B. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999, 282(22):2131-2135.
78. Gordon S. Macrophage heterogeneity and tissue lipids. J Clin Invest 2007, 117(1):89-93.
79. Lumeng C.N., Bodzin J.L., Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007, 117(1):175-184.
80. Lesser G.T., Deutsch S. Measurement of adipose tissue blood flow and perfusion in man by uptake of 85Kr. J Appl Physiol 1967, 23(5):621-630.
81. Rutkowski J.M., Davis K.E., Scherer P.E. Mechanisms of obesity and related pathologies: the macro- and microcirculation of adipose tissue. FEBS J 2009, 276(20):5738-5746.
82. Van d V., Pauwels B., Boydens C., Decaluwe K. Adipocytokines in relation to cardiovascular disease. Metabolism 2013, 62(11):1513-1521.
83. Pasarica M., Sereda O.R., Redman L.M., et al. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 2009, 58(3):718-725.
84. Trayhurn P., Wang B., Wood I.S. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity?. Br J Nutr 2008, 100(2):227-235.
85. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112(12):1796-1808.
86. Hernandez-Pando R., Bornstein Q.L., Aguilar L.D., Orozco E.H., Madrigal V.K., Martinez C.E. Inflammatory cytokine production by immunological and foreign body multinucleated giant cells. Immunology 2000, 100(3):352-358.
87. Cinti S., Mitchell G., Barbatelli G., et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005, 46(11):2347-2355.
88. Gray S.L., Vidal-Puig A.J. Adipose tissue expandability in the maintenance of metabolic homeostasis. Nutr Rev 2007, 65(6 Pt 2):S7-S12.
89. Tchernof A., Despres J.P. Pathophysiology of human visceral obesity: an update. Physiol Rev 2013, 93(1):359-404.
90. Bjorntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990, 10(4):493-496.
91. Mauriege P., Despres J.P., Moorjani S., et al. Abdominal and femoral adipose tissue lipolysis and cardiovascular disease risk factors in men. Eur J Clin Invest 1993, 23(11):729-740.
92. Nicholls S., Lundman P. The emerging role of lipoproteins in atherogenesis: beyond LDL cholesterol. Semin Vasc Med 2004, 4(2):187-195.
93. Jensen M.D. Is visceral fat involved in the pathogenesis of the metabolic syndrome? Human model. Obesity (Silver Spring) 2006, 14(Suppl. 1):20S-24S.
94. Tribble D.L., Holl L.G., Wood P.D., Krauss R.M. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992, 93(3):189-199.
95. Lamarche B., Despres J.P., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular Study). Am J Cardiol 1995, 75(17):1189-1195.
96. Pouliot M.C., Despres J.P., Nadeau A., et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 1992, 41(7):826-834.
97. Anderson T.J., Gregoire J., Hegele R.A., et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013, 29(2):151-167.
98. Brochu M., Tchernof A., Dionne I.J., et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women?. J Clin Endocrinol Metab 2001, 86(3):1020-1025.
99. Tchernof A., Lamarche B., Prud'Homme D., et al. The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 1996, 19(6):629-637.
100. Mathieu P., Pibarot P., Larose E., Poirier P., Marette A., Despres J.P. Visceral obesity and the heart. Int J Biochem Cell Biol 2008, 40(5):821-836.
101. von EA, Nofer J.R., Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001, 21(1):13-27.
102. Navab M., Reddy S.T., Van Lenten B.J., Fogelman A.M. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011, 8(4):222-232.
103. Navab M., Anantharamaiah G.M., Fogelman A.M. The role of high-density lipoprotein in inflammation. Trends Cardiovasc Med 2005, 15(4):158-161.
104. Ansell B.J., Watson K.E., Fogelman A.M., Navab M., Fonarow G.C. High-density lipoprotein function recent advances. J Am Coll Cardiol 2005, 46(10):1792-1798.
105. Despres J.P., Lemieux I., Dagenais G.R., Cantin B., Lamarche B. HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis 2000, 153(2):263-272.
106. Ansell B.J., Navab M., Hama S., et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003, 108(22):2751-2756.
107. Roberts C.K., Katiraie M., Croymans D.M., Yang O.O., Kelesidis T. Untrained Young Men Have Dysfunctional HDL Compared to Strength Trained Men Irrespective of Overweight/Obesity Status. J Appl Physiol 2013, 115(7):1043-1049.
108. Ouchi N., Ohishi M., Kihara S., et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003, 42(3):231-234.
109. Northcott J.M., Yeganeh A., Taylor C.G., Zahradka P., Wigle J.T. Adipokines and the cardiovascular system: mechanisms mediating health and disease. Can J Physiol Pharmacol 2012, 90(8):1029-1059.
110. Asayama K., Hayashibe H., Dobashi K., et al. Decrease in serum adiponectin level due to obesity and visceral fat accumulation in children. Obes Res 2003, 11(9):1072-1079.
111. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372(6505):425-432.
112. Dyck D.J., Heigenhauser G.J., Bruce C.R. The role of adipokines as regulators of skeletal muscle fatty acid metabolism and insulin sensitivity. Acta Physiol (Oxf) 2006, 186(1):5-16.
113. Unger R.H. Lipotoxic diseases. Annu Rev Med 2002, 53:319-336.
114. Couillard C., Lamarche B., Mauriege P., et al. Leptinemia is not a risk factor for ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Diabetes Care 1998, 21(5):782-786.
115. Wallace A.M., McMahon A.D., Packard C.J., et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001, 104(25):3052-3056.
116. Villarreal-Molina M.T., Antuna-Puente B. Adiponectin: anti-inflammatory and cardioprotective effects. Biochimie 2012, 94(10):2143-2149.
117. Frystyk J., Berne C., Berglund L., Jensevik K., Flyvbjerg A., Zethelius B. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 2007, 92(2):571-576.
118. Nilsson P.M., Engstrom G., Hedblad B., et al. Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance. Arterioscler Thromb Vasc Biol 2006, 26(12):2758-2762.
119. Goldstein B.J., Scalia R.G., Ma X.L. Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med 2009, 6(1):27-35.
120. Yin W.H., Wei J., Huang W.P., Chen J.W., Young M.S., Lin S.J. Prognostic value of circulating adipokine levels and expressions of adipokines in the myocardium of patients with chronic heart failure. Circ J 2012, 76(9):2139-2147.
121. Shinmura K. Is adiponectin a bystander or a mediator in heart failure? The tangled thread of a good-natured adipokine in aging and cardiovascular disease. Heart Fail Rev 2010, 15(5):457-466.
122. Tan B.K., Adya R., Randeva H.S. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med 2010, 20(5):143-148.
123. Frye R.L., August P., Brooks M.M., et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009, 360(24):2503-2515.
124. Chen X., Yang L., Zhai S.D. Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies. Chin Med J (Engl) 2012, 125(23):4301-4306.
125. Bertrand O.F., Poirier P., Rodes-Cabau J., et al. Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial. Atherosclerosis 2010, 211(2):565-573.
126. Estruch R., Ros E., Salas-Salvado J., et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013, 368(14):1279-1290.
127. Wing R.R., Bolin P., Brancati F.L., et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013, 369(2):145-154.
128. Despres J.P., Poirier P. Diabetes: Looking back at Look AHEAD-giving lifestyle a chance. Nat Rev Cardiol 2013, 10(4):184-186.